179 related articles for article (PubMed ID: 9161731)
21. DNA ploidy and nuclear morphometry in adult intracranial ependymomas.
Onguru O; Ulutin C; Celasun B; Gunhan O
Clin Neuropathol; 2003; 22(6):266-72. PubMed ID: 14672504
[TBL] [Abstract][Full Text] [Related]
22. Ependymoma: a heterogeneous tumor of uncertain origin and limited therapeutic options.
Dorfer C; Tonn J; Rutka JT
Handb Clin Neurol; 2016; 134():417-31. PubMed ID: 26948369
[TBL] [Abstract][Full Text] [Related]
23. Tumor vessel biology in pediatric intracranial ependymoma.
Wagemakers M; Sie M; Hoving EW; Molema G; de Bont ES; den Dunnen WF
J Neurosurg Pediatr; 2010 Apr; 5(4):335-41. PubMed ID: 20367336
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
25. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma.
Ho DM; Hsu CY; Wong TT; Chiang H
J Neurooncol; 2001 Aug; 54(1):77-85. PubMed ID: 11763426
[TBL] [Abstract][Full Text] [Related]
26. Ependymoma.
Teo C; Nakaji P; Symons P; Tobias V; Cohn R; Smee R
Childs Nerv Syst; 2003 Jun; 19(5-6):270-85. PubMed ID: 12761644
[TBL] [Abstract][Full Text] [Related]
27. The biology of ependymomas and emerging novel therapies.
Saleh AH; Samuel N; Juraschka K; Saleh MH; Taylor MD; Fehlings MG
Nat Rev Cancer; 2022 Apr; 22(4):208-222. PubMed ID: 35031778
[TBL] [Abstract][Full Text] [Related]
28. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
29. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
[TBL] [Abstract][Full Text] [Related]
30. Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma.
Michalowski MB; de Fraipont F; Michelland S; Entz-Werle N; Grill J; Pasquier B; Favrot MC; Plantaz D
Cancer Genet Cytogenet; 2006 Apr; 166(1):74-81. PubMed ID: 16616114
[TBL] [Abstract][Full Text] [Related]
31. Expression of platelet-derived growth factor transcripts in medulloblastomas and ependymomas.
Black P; Carroll R; Glowacka D
Pediatr Neurosurg; 1996; 24(2):74-8. PubMed ID: 8841077
[TBL] [Abstract][Full Text] [Related]
32. Further understanding of the pathology of glioma: implications for the clinic.
Camelo-Piragua S; Kesari S
Expert Rev Neurother; 2016 Sep; 16(9):1055-65. PubMed ID: 27228211
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of chromosome 1q gain in intracranial ependymomas.
Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
[TBL] [Abstract][Full Text] [Related]
34. Molecular cytogenetic studies of pediatric ependymomas.
Kramer DL; Parmiter AH; Rorke LB; Sutton LN; Biegel JA
J Neurooncol; 1998 Mar; 37(1):25-33. PubMed ID: 9525835
[TBL] [Abstract][Full Text] [Related]
35. Understanding Ependymoma Oncogenesis: an Update on Recent Molecular Advances and Current Perspectives.
Gupta K; Salunke P
Mol Neurobiol; 2017 Jan; 54(1):15-21. PubMed ID: 26712502
[TBL] [Abstract][Full Text] [Related]
36. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
37. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients.
Korshunov A; Golanov A; Sycheva R; Timirgaz V
Cancer; 2004 Mar; 100(6):1230-7. PubMed ID: 15022291
[TBL] [Abstract][Full Text] [Related]
38. WHO Grade II and III supratentorial hemispheric ependymomas in adults: case series and review of treatment options.
Niazi TN; Jensen EM; Jensen RL
J Neurooncol; 2009 Feb; 91(3):323-8. PubMed ID: 18974933
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the NF2 gene in oligodendrogliomas and ependymomas.
Alonso ME; Bello MJ; Arjona D; Gonzalez-Gomez P; Lomas J; de Campos JM; Kusak ME; Isla A; Rey JA
Cancer Genet Cytogenet; 2002 Apr; 134(1):1-5. PubMed ID: 11996787
[TBL] [Abstract][Full Text] [Related]
40. Pediatric supratentorial ependymomas show more frequent deletions on chromosome 9 than infratentorial ependymomas: a microsatellite analysis.
Schneider D; Monoranu CM; Huang B; Rutkowski S; Gerber NU; Krauss J; Puppe B; Roggendorf W
Cancer Genet Cytogenet; 2009 Jun; 191(2):90-6. PubMed ID: 19446744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
